IL324083A - פורמולציה של מרופיטנט - Google Patents

פורמולציה של מרופיטנט

Info

Publication number
IL324083A
IL324083A IL324083A IL32408325A IL324083A IL 324083 A IL324083 A IL 324083A IL 324083 A IL324083 A IL 324083A IL 32408325 A IL32408325 A IL 32408325A IL 324083 A IL324083 A IL 324083A
Authority
IL
Israel
Prior art keywords
maropitant
pharmaceutical composition
butanol
composition according
formulation
Prior art date
Application number
IL324083A
Other languages
English (en)
Original Assignee
Vetviva Richter Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vetviva Richter Gmbh filed Critical Vetviva Richter Gmbh
Publication of IL324083A publication Critical patent/IL324083A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL324083A 2023-04-25 2025-10-20 פורמולציה של מרופיטנט IL324083A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA50310/2023A AT527172A1 (de) 2023-04-25 2023-04-25 Maropitantformulierung
PCT/AT2024/060169 WO2024221029A1 (de) 2023-04-25 2024-04-24 Maropitantformulierung

Publications (1)

Publication Number Publication Date
IL324083A true IL324083A (he) 2025-12-01

Family

ID=91276969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324083A IL324083A (he) 2023-04-25 2025-10-20 פורמולציה של מרופיטנט

Country Status (6)

Country Link
EP (1) EP4701623A1 (he)
AT (1) AT527172A1 (he)
AU (1) AU2024262341A1 (he)
IL (1) IL324083A (he)
MX (1) MX2025012499A (he)
WO (1) WO2024221029A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA27776C2 (uk) 1991-05-31 2000-10-16 Пфайзер Інк. Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
CA2189501A1 (en) 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
BRPI0507301A (pt) * 2004-01-30 2007-06-26 Pfizer Prod Inc composições farmacêuticas de antagonistas do receptor de nuerocinina e ciclodextrina e métodos para melhor toleráncia no local de injeção
MXPA06007964A (es) * 2004-01-30 2007-01-26 Pfizer Prod Inc Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia.
JP5021318B2 (ja) 2004-01-30 2012-09-05 ファイザー・プロダクツ・インク β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
NL2015865B1 (en) * 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.

Also Published As

Publication number Publication date
MX2025012499A (es) 2025-11-03
AT527172A1 (de) 2024-11-15
AU2024262341A1 (en) 2025-11-13
WO2024221029A1 (de) 2024-10-31
EP4701623A1 (de) 2026-03-04

Similar Documents

Publication Publication Date Title
EP2785352B1 (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
EP0546018B1 (en) Pharmaceutical composition of florfenicol
KR100533407B1 (ko) Ｎｍｄａ 수용체 작용제 약학 조성물
KR20090040248A (ko) 화합물의 비경구 전달을 위한 제형 및 이의 용도
TWI544934B (zh) 含有氟喹諾酮抗生素藥物之經改良藥學組成物
JP2003506416A (ja) モキシフロキサシン／塩化ナトリウム製剤
CA2902823C (en) Intrathecal hydromorphone solutions having improved stability
US6288080B1 (en) Magnesium quinolone antibiotics
RS62057B1 (sr) Formulacija maropitanta
IL324083A (he) פורמולציה של מרופיטנט
CA3289893A1 (en) Maropitant formulation
US20220000853A1 (en) Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
US7868016B2 (en) Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US20030153581A1 (en) Stabilized difloxacin injectable solution
EP0365363B1 (en) Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine
CA2626273C (en) Cefquinome compositions and methods of their use
WO1994026110A1 (en) Stable quinolone and naphthyridine premix formulations
CN118714999A (zh) 不含对羟基苯甲酸酯的非索非那定制剂
WO2007069070A2 (en) Aseptically filled multidose injectable dosage forms of granisetron
WO2014139677A1 (en) Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations
PL195593B1 (pl) Weterynaryjny środek leczniczy przeciwko drobnoustrojom chorobotwórczym